Duodenal mucosal resurfacing (DMR), a new-style endoscopic procedure using hydrothermal energy to ablate this thickened layer ...

Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered ...

Data from Phase 2 Trial VGX-001-012 of Mizagliflozin in Post Bariatric Hypoglycemia will be Presented RALEIGH, NC / ACCESS Newswire / April 15, 2025 /Vogenx, Inc., a clinical-stage developer of novel ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

Mounjaro (Terzepatide) is a dual GLP-1/GIP (Gastric Inhibitory Peptide) receptor agonist, which may offer better blood sugar control and enhanced weight loss compared to traditional GLP-1 agonists.

Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...

both alone and in combination with the glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide. The study demonstrated significant improvements in appetite suppression ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...